OBJECTIVES: To clarify the real-world trends and treatment duration of patients with 1st and 2nd stage syphilis using integrated data of IQVIA Claims, JAST and DeSC database.

METHODS: Patients with syphilis (ICD-10: A51, A52) and corresponding treatment who have 6 months follow-up and 6 months look-back period in the IQVIA Claims, JAST and the DeSC database were identified. IQVIA Claims and JAST database contains the payer claims data of the health insurance union for Japanese workers. The DeSC database contains national health insurance (provided for individuals below 75 years of age who are not covered by other public health insurance); and later-stage elderly healthcare system (provided for individuals over 75 years old). The data period was between April 2015 and June 2022. Patients’ demographics, treatment duration, and HCRU were described.

RESULTS: Of 440 patients with definitive diagnosis of syphilis who received syphilis treatment (Amoxicillin, Benzylpenicillin, Spiramycin, Minocycline), 342 (77.7%) patients were male, and 98 (22.3%) patients were female. Mean(SD) age for male and female was 42(12.5) and 35.4(15.2), respectively, whereas the median(1st quantiles, 3rd quantiles) was 41(32, 51) and 31(24, 43), respectively. The majority of patients were treated with oral penicillin. Mean treatment duration was 38.2 days in all patients and 38.8 days in 1st stage syphilis patients, whereas the median was 28 days and 29 days, respectively.

CONCLUSIONS: The majority of patients with syphilis was male in our study, which is consistent with the reported cases by WHO (2022). The patients in our study were slightly older compared to the report by WHO, who were in the late 20s in the US. To our knowledge, this is the first time report about the treatment, frequency of test and HCRU for patients with syphilis in Japan real-world setting. Further details will be discussed in the poster.